Clinical and experimental rheumatology

The rheumatic diseases, such as rheumatoid arthritis (RA), spondylarthritis and systemic lupus erythematosus (SLE) belong to the endemic diseases, affecting more than 1 percent of the population of Sweden.

The immune system which protects us from bacterial and viral infections may in certain individuals with genetic susceptibility which are exposed to certain environmental factors loose its tolerance and attack endogenous tissues and organs. Knowledge on the etiology of rheumatic disease is increasing, and the number of treatment options for patients who suffer has risen dramatically in recent years.

My group is studying underlying mechanisms for rheumatic diseases, especially SLE, as well as biomarkers and autoantibodies in relation to diagnosis, treatment response and prognosis.


News

Publications

Selected publications

Conformational state of C-reactive protein is critical for reducing immune complex-triggered type I interferon response: Implications for pathogenic mechanisms in autoimmune diseases imprinted by type I interferon gene dysregulation

Svanberg C, Enocsson H, Govender M, Martinsson K, Potempa LA, Rajab IM, Fernandez-Botran R, Wetterö J, Larsson M och Sjöwall C.

Journal of Autoimmunity, 2023-02-01, Volume 135, Article 102998, Copyright © 2023 The Authors

Graphical Abstract.

C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205

Enocsson H, Gullstrand B, Eloranta M-L, Wetterö J, Leonard D, Rönnblom L, Bengtsson A och Sjöwall C.

Front. Immunol., 28 January 2021 | https://doi.org/10.3389/fimmu.2020.622326

Figure 2 CRP levels among patients with and without detectable IL-6 levels (Z-axis) along with different CRP genotype (rs1205) and type I IFN gene signature (IGS) status (X-axis). Bars show median values.

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Autoimmun. 2020 Jan;106:102340. doi: 10.1016/j.jaut.2019.102340. Epub 2019 Oct 17. (pubmed)

Bilder Christopher Sjöwall forskningsledare.

Latest publications in DiVA

2023

Agnes Torell, Marit Stockfelt, Gunilla Larsson, Kaj Blennow, Henrik Zetterberg, Dag Leonard, Lars Roennblom, Muna Atallah Saleh, Christopher Sjöwall, Helena Strevens, Andreas Joensen, Anders A. Bengtsson, Estelle Trysberg, Maria Majcuk Sennstroem, Agneta Zickert, Elisabet Svenungsson, Iva Gunnarsson, Karin Christenson, Johan Bylund, Bo Jacobsson, Anna Rudin, Anna-Carin Lundell (2023) Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus Arthritis Research & Therapy, Vol. 25, Article 107 Continue to DOI

About me

Program teaching

  • Medical programme
  • Biomedical Laboratory Science Programme
  • Doctoral studies

Network

  • Chairman of Working group for Biosimilars in Rheumatology (Swedish Society for Rheumatology, since 2014)
  • Member of the Working group that compose Guidelines for the medical treatment of SLE with an annual update (Swedish Society for Rheumatology, since 2014)
  • Consultant for the Dental and Pharmaceutical Benefits Agency (TLV) in the review and renegotiation of prices for Biologics in Sweden (since 2015)

Organisation